A strain of Staphylococcus epidermidis and its application
Through the biological preparation of Staphylococcus epidermis LY1 strain, the immune dysfunction caused by symbiotic bacteria disorder in the nasopharyngeal area is solved, which significantly inhibits EB virus infection and regulates mucosal immune response, and provides an effective anti-pathogen infection and mucosal immune regulation. drugs or probiotic preparations.
Patent Information
- Application Number
- CN202410162753.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-02-05
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2044-02-05
AI Technical Summary
Disturbance of nasopharyngeal symbiotic flora leads to dysfunction of the nasopharyngeal mucosa, increasing susceptibility to pathogenic pathogens and the risk of infection. The prior art is difficult to effectively inhibit EB virus infection and regulate mucosal immune response.
Staphylococcus epidermidis LY1 strain is used to prepare biological agents by culturing them in BHI culture medium to inhibit pathogen infection, anti-EB virus infection and regulate mucosal immune response. The dosage form can be an oral liquid, spray or powder.
Staphylococcus epidermis LY1 significantly assists epithelial cells in resisting EB virus infection, inhibits the growth of various pathogens, and regulates mucosal immune response. It has potential application of probiotic preparations for the prevention and treatment of acute and chronic nasopharyngeal diseases and nasopharyngeal carcinoma.
Smart Images

Figure CN118126875B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and particularly relates to a strain of Staphylococcus epidermidis and application thereof in preparing drugs for inhibiting pathogen infection, resisting EB virus infection and regulating mucosal immune response. Background Art
[0002] The nasopharynx is an important part of the upper respiratory tract. It is anatomically connected to the outside world through the nasal cavity and oral cavity. Its warm and humid environment is conducive to the colonization and growth of microorganisms. In the early stages of life, nasopharyngeal microorganisms originate from the mother's skin, vagina and breast milk, and then gradually develop into a unique ecological niche. In healthy adults, the dominant symbiotic bacteria colonizing the nasopharynx include Staphylococcus, Corynebacterium, Cutibacterium and Dolosigranulum. These nasopharyngeal native flora can defend human respiratory health in many ways. For example, symbiotic bacteria on the mucosal surface can effectively prevent pathogens from colonizing on its surface through colonization resistance. These symbiotic bacteria can also jointly resist the invasion of pathogenic microorganisms by regulating the inflammation and immune status of the mucosa, or cooperating with the human immune system.
[0003] Under physiological conditions, the nasopharyngeal mucosal immunity that has co-evolved with the nasopharyngeal flora has a strong resistance to infection by a variety of pathogens and can initiate the clearance of pathogens by producing a variety of immune regulatory factors. However, when the nasopharyngeal symbiotic flora is disturbed and the nasopharyngeal mucosal immune function is dysregulated, the nasopharynx may become more susceptible to pathogenic pathogens or have a reduced clearance ability, leading to the occurrence and development of acute and chronic nasopharyngeal diseases. Therefore, regulating the nasopharyngeal symbiotic flora and inducing the nasopharyngeal mucosa to produce a high level of mucosal immune response is promising in the prevention and treatment of nasopharyngeal anti-infection and related diseases.
[0004] Staphylococci are important symbiotic bacteria in the human body, widely colonizing in many parts of the body, such as the nasopharynx and skin. Among them, Staphylococcus epidermidis has been reported to help nasopharyngeal epithelial cells resist influenza virus invasion and inhibit infectious diseases caused by Staphylococcus aureus. Given the protective effect of symbiotic flora on nasopharyngeal diseases, Staphylococcus bacteria that coexist in the nasopharynx of healthy adults may have beneficial effects in helping nasopharyngeal epithelial cells resist infection by pathogens such as Epstein-Barr virus infection and regulating mucosal immune responses, and are candidate probiotics for the prevention and treatment of acute and chronic nasopharyngeal diseases and nasopharyngeal carcinoma. Summary of the invention
[0005] In order to overcome the above-mentioned shortcomings and deficiencies of the prior art, the primary purpose of the present invention is to provide a strain of Staphylococcus epidermidis. The Staphylococcus epidermidis of the present invention has good antiviral, antibacterial and mucosal immune response regulating abilities and can be used as a novel respiratory probiotic preparation.
[0006] Another object of the present invention is to provide a biological preparation based on the above-mentioned Staphylococcus epidermidis.
[0007] Another object of the present invention is to provide the use of the above-mentioned Staphylococcus epidermidis in the preparation of drugs for inhibiting pathogen infection, resisting EB virus infection and regulating mucosal immune response.
[0008] The purpose of the present invention is achieved through the following solutions:
[0009] A strain of Staphylococcus epidermidis, named Staphylococcus epidermidis LY1, was deposited in Guangdong Microbiological Culture Collection Center, abbreviated as GDMCC, address: Institute of Microbiology, Guangdong Academy of Sciences, 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, with a deposit number of GDMCC No: 64350 and a deposit date of January 31, 2024.
[0010] The colonies of the Staphylococcus epidermidis on the CBA blood plate are milky white and quasi-circular, with a moist and smooth surface, neat edges, no pigmentation, and obvious protrusions.
[0011] A biological preparation is prepared based on the above-mentioned Staphylococcus epidermidis.
[0012] Furthermore, the biological preparation can be obtained by culturing the above-mentioned Staphylococcus epidermidis in BHI medium.
[0013] The present invention also provides the use of the Staphylococcus epidermidis in the preparation of medicines or probiotic preparations against pathogenic microorganisms.
[0014] The present invention also provides the use of the above biological preparation in the preparation of medicines or probiotic preparations against pathogenic microorganisms.
[0015] Furthermore, the pathogenic microorganisms may include Epstein-Barr virus, Staphylococcus aureus, Fusobacterium nucleatum and Prevotella intermedia.
[0016] The present invention also provides the use of the Staphylococcus epidermidis in the preparation of medicines or probiotic preparations for inhibiting pathogen infection or regulating mucosal immune response.
[0017] The present invention also provides the use of the Staphylococcus epidermidis in the preparation of medicines or probiotic preparations for resisting EB virus infection.
[0018] The present invention also provides the use of the above biological preparation in the preparation of medicines or probiotic preparations for inhibiting pathogen infection or regulating mucosal immune response.
[0019] The present invention also provides the use of the above biological preparation in the preparation of medicines or probiotic preparations for resisting EB virus infection.
[0020] Furthermore, the pathogens are microorganisms (including bacteria, viruses, rickettsia, fungi), parasites or other agents (microorganism recombinants including hybrids or mutants) that can cause diseases in humans, animals and plants. Specifically, they may include Epstein-Barr virus, Staphylococcus aureus, Fusobacterium nucleatum and Prevotella intermedia.
[0021] Furthermore, the medicine or probiotic preparation contains the Staphylococcus epidermidis strain, or a culture product thereof, or a fermentation culture fluid thereof, or a filtrate of a fermentation culture fluid thereof.
[0022] Furthermore, the medicine or probiotic preparation may be in the form of an oral liquid, a spray or a powder.
[0023] Compared with the prior art, the present invention has the following advantages and beneficial effects:
[0024] The Staphylococcus epidermidis strain of the present invention is derived from the nasopharynx of healthy people, can colonize in the human nasopharynx, has the activity of inhibiting pathogen infection, resisting Epstein-Barr virus infection and regulating mucosal immune response, can significantly assist the epithelium in resisting Epstein-Barr virus infection, and inhibiting a variety of pathogens. It is expected to be developed into a drug or probiotic preparation for resisting pathogen infection and regulating mucosal immunity. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.
[0026] Figure 1 This is the colony morphology of Staphylococcus epidermidis LY1.
[0027] Figure 2 This is the Gram staining result of Staphylococcus epidermidis LY1.
[0028] Figure 3 To screen Staphylococcus epidermidis in 293T cell line that has the function of inhibiting the efficiency of epithelial cell infection with Epstein-Barr virus.
[0029] Figure 4This is a fluorescent imaging image of the inhibitory effect of Staphylococcus epidermidis LY1 on EB virus.
[0030] Figure 5 This is a statistical chart showing the inhibitory effect of Staphylococcus epidermidis LY1 on EB virus.
[0031] Figure 6 The effect of Staphylococcus epidermidis LY1 on cell viability.
[0032] Figure 7 The antibacterial ability of Staphylococcus epidermidis LY1 on pathogens. A: The effect of Staphylococcus epidermidis LY1 on the growth of Staphylococcus aureus; B: The effect of Staphylococcus epidermidis LY1 on the growth of Prevotella intermedia; C: The effect of Staphylococcus epidermidis LY1 on the growth of Fusobacterium nucleatum.
[0033] Figure 8 The effect of Staphylococcus epidermidis LY1 on the innate immunity level.
[0034] Among them, *P<0.05; **P<0.01; ***P<0.001. DETAILED DESCRIPTION
[0035] The present invention is further described in detail below in conjunction with examples, but the embodiments of the present invention are not limited thereto. The materials involved in the following examples can be obtained from commercial channels unless otherwise specified. The methods described are conventional methods unless otherwise specified.
[0036] Example 1: Isolation, purification and preservation of Staphylococcus aureus
[0037] 1.1 Sample collection and staphylococcal isolation
[0038] Nasopharyngeal swab samples were collected from the nasopharynx of 6 healthy adult volunteers. A total of 416 bacterial monoclones were isolated from 6 Staphylococcus genera, of which 149 belonged to Staphylococcus epidermidis. Finally, a strain of Streptococcus epidermidis with the strongest protective effect was screened out. The method for collecting nasopharyngeal swabs is as follows: insert a sterile nasopharyngeal swab into the nasopharynx of a healthy volunteer through the nasal cavity, rotate it repeatedly, and evenly wipe the walls of the nasopharynx and the pharyngeal crypts. After the swab has fully absorbed the wiped tissue, take it out and put it into a sterile collection tube. Open the nasopharyngeal swab collection tube in the clean bench, add 500 μL of sterile PBS solution, repeatedly blow and mix, and perform 10-fold gradient dilutions in sequence. Take 10 respectively. -3 , 10 -4 , 10 -550 μL of gradient dilution was evenly spread on CBA blood plate, placed in a 37°C constant temperature incubator, and inverted for 24 hours. After the single colony grew, 100 clones were picked and spread on a new CBA blood plate for sub-isolation and purification and culture for 24 hours. For the sub-isolation and purification colonies, matrix-assisted laser desorption / ionization time-of-flight mass spectrometry was used for species identification.
[0039] 1.2 Molecular identification of Staphylococcus epidermidis LY1
[0040] Single colonies were picked, genomic DNA was extracted using a bacterial genomic DNA extraction kit (Tiangen, China), and PCR amplification was performed using the 16S rRNA gene universal primers 27F (5'-AGRGTTYGATYMTGGCTCAG-3') and 1492R (5'-RGYTACCTTGTTACGACTT-3') as upstream and downstream primers. The PCR amplification product was sent to Beijing Ruibo Xingke Biotechnology Co., Ltd. for Sanger sequencing. After NCBI Blast alignment, the obtained sequence had a sequence similarity of more than 99% with multiple classical strains of Staphylococcus epidermidis, confirming its classification and naming as Staphylococcus epidermidis, named Staphylococcus epidermidis LY1. The 16S rRNA gene sequence fragment is as follows:
[0041]
[0042] The colonies of Staphylococcus epidermidis LY1 on CBA blood agar plates are milky white, quasi-circular, with a moist, smooth surface, neat edges, no pigmentation, and obvious protrusions. See the colony morphology of Staphylococcus epidermidis for details. Figure 1 Under an optical microscope, the bacteria are spherical, arranged singly, in pairs, or in grape-like clusters, without flagella or spores, and are Gram-positive. Figure 2 .
[0043] 1.3 The biochemical identification results of Staphylococcus epidermidis LY1 are shown in Table 1:
[0044] Table 1
[0045] test result test result Anaerobic growth + ONPG + Aerobic growth + Urea + power + Salicin - Oxidase - Escin - glycerin + Mannitol - Indigo - Raffinose - Ornithine - Ammonium Gluconate + mucus acid - Citrate -
[0046] "+" indicates a positive result, and "-" indicates a negative result.
[0047] 1.4 Preservation of Staphylococcus epidermidis LY1: The strain was deposited in Guangdong Microbiological Culture Collection Center, referred to as GDMCC, on January 31, 2024. The address is: Institute of Microbiology, Guangdong Academy of Sciences, 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, with the deposit number GDMCC No: 64350.
[0048] Example 2: Anti-EB virus effect of Staphylococcus epidermidis LY1
[0049] 2.1 Preparation of free EBV
[0050] Use Akata (EBV-eGFP) cell line to prepare free EBV. Select rEBV with good culture status and high GFP positive rate + Akata cells (purchased from Guangzhou Genio Biotechnology Co., Ltd.) were cultured in 1640 medium containing 700 μg / mL G418 and 10% fetal bovine serum for 3 days for drug resistance screening to increase the proportion of EB virus-positive cells. + The cell expansion system was cultured to 2000 mL and the cell concentration was adjusted to 2×10 6 / mL, and add sIgG (0.8% anti-human IgG antibody) to induce for 6h. During this period, shake the cells every 2h to prevent the cells from aggregating. After the induction is completed, collect the cells and centrifuge (1500rpm, 10min). Remove the supernatant, add 1640 medium containing 3.5% fetal bovine serum and continue to culture for 72h to allow the cells to fully lyse and release the virus. After the culture is completed, centrifuge at 4°C, 4000rpm, collect the cell supernatant, and then use a 0.45μm filter to filter the residual cells and their fragments. The filtered supernatant is subjected to ultra-high speed centrifugation (50000g, 2h) to enrich the virus particles in the supernatant. Finally, use serum-free 1640 to resuspend the virus particles, and concentrate the virus solution by 100 times the volume, that is, use 1mL of serum-free 1640 to resuspend the virus particles from 100mL supernatant centrifuged, and divide them into 500μL-1mL / tube and store them in a -80℃ refrigerator.
[0051] 2.2 Inhibition of EBV infection in epithelial cells by Staphylococcus epidermidis LY1
[0052] One day before the experiment, nasopharyngeal carcinoma epithelial cells HNE1 (Nat Microbiol. 2018 Feb; 3(2): 1-8.) and human embryonic kidney cells 293T (purchased from ATCC, CRL-3216) were cultured at 2×10 4 The cells were inoculated into a 48-well plate at a density of 10 cells and cultured in a 37°C incubator for 24 h. The single clone of the Staphylococcus epidermidis strain was inoculated into 10 mL of BHI medium and cultured aerobically at 37°C and 220 rpm for 12 h. The cells were centrifuged at 3000 rpm for 5 min, the supernatant was removed, and the cells were resuspended in 1640 culture medium. The OD was measured. 600 Count, add to HNE1 and 293T cell lines at a multiplicity of infection of MOI = 10, that is, the ratio of bacteria to cells = 10:1, respectively, and the control group is a group without bacteria, and co-culture in a 37°C incubator for 4 hours. Then remove the co-culture supernatant, wash 3 times with PBS, and replace the medium containing a final concentration of 250μg / mL vancomycin for 24 hours, and then add free EB virus to co-culture with the cells. After 24 hours, trypsin was used to digest the cells, and the cells were fixed with 4% paraformaldehyde. The proportion of GFP-positive cells, that is, the proportion of cells infected with EB virus, was detected by flow cytometry.
[0053] A total of 149 Staphylococcus epidermidis clones were isolated from nasopharyngeal swabs of 6 healthy donors, and 2-3 clones with good growth activity were further selected from each donor to carry out the above experiment in the 293T cell line. After comprehensive screening, Staphylococcus epidermidis LY1 (i.e., Staphylococcus epidermidis-1) was the most significant in reducing the proportion of EB virus-infected epithelial cells ( Figure 3). The other isolated Staphylococcus epidermidis strains also have a certain effect of inhibiting EB virus infection of epithelial cells. The nasopharyngeal commensal bacteria Staphylococcus ureilyticus isolated in the same period only slightly reduced the efficiency of EB virus infection of epithelial cells, and Staphylococcus haemolyticus even promoted the efficiency of EB virus infection of epithelial cells to a certain extent. In order to further evaluate the function of the preferred Staphylococcus epidermidis LY1 in inhibiting EB virus infection of epithelial cells, the effect of the Staphylococcus epidermidis LY1 of the present invention in inhibiting EB virus infection of epithelial cells was further verified in the HNE1 cell line ( Figure 4 and Figure 5 ). As can be seen from the figure, the proportion of epithelial cells infected by EB virus was significantly reduced after treatment with Staphylococcus epidermidis LY1.
[0054] Example 3: Evaluation of cytotoxicity of Staphylococcus epidermidis
[0055] One day before the experiment, nasopharyngeal carcinoma epithelial cells HNE1 and gastric cancer epithelial cells AGS (purchased from ATCC, CRL1739) were cultured at 4×10 4 The cells were inoculated into a 24-well plate at a density of 10 cells and cultured in a 37°C incubator for 24 h. The Staphylococcus epidermidis LY1 monoclonal was inoculated into 10 mL BHI medium and cultured aerobically at 37°C and 220 rpm for 12 h. The cells were centrifuged at 3000 rpm for 5 min, the supernatant was removed, and the cells were resuspended in 1640 culture medium. The OD was measured. 600 The cells were counted and added to HNE1 and AGS cell lines at an infection multiplicity of 10 (i.e., a bacteria: cell ratio of 10:1). The control group was a group without bacteria. The cells were incubated at 37°C for 4 h, and then the culture supernatant was removed. The cells were washed three times with PBS, and the cells were digested with trypsin. The cells were resuspended in a medium containing a final concentration of 250 μg / mL vancomycin, counted with a counter, and re-plated into a 96-well plate (1.5×10 3 / well), CCK8 reagent was added after 24h, 48h, 72h and 96h, 10μL CCK8 per well, incubated in a 37℃ oven for 2h, and OD was measured. 450 The effects of Staphylococcus epidermidis LY1 stimulation on the proliferation of nasopharyngeal carcinoma epithelial cells and gastric cancer epithelial cells were detected. Figure 6 It was shown that the co-incubation of Staphylococcus epidermidis LY1 and epithelial cells for 4 h at MOI=10 did not affect the proliferation of cells, that is, the Staphylococcus epidermidis LY1 of the present invention had no obvious toxic effect on epithelial cells.
[0056] Example 4: Antibacterial effect of Staphylococcus epidermidis LY1
[0057] The Staphylococcus epidermidis LY1 monoclone was inoculated into 10 mL BHI medium and cultured aerobically at 37 ° C 220 rpm for 12 h and anaerobically in the anaerobic culture system for 12 h. The bacterial culture supernatant was then collected by centrifugation at 3000 rpm for 5 min and filtered with a 0.22 μm filter to remove bacteria and debris. The aerobic culture supernatant was added to the culture system of the opportunistic pathogen Staphylococcus aureus (ATCC_12600) in different proportions; the anaerobic culture supernatant was added to the culture system of the opportunistic pathogen Fusobacterium nucleatum subsp. Nucleatum (ATCC_25586) and Prevotella intermedia (ATCC_25611). The specific operation is as follows: based on the consistency of the total culture system, the control group added 10mL BHI medium, and the experimental group was graded diluted, adding 5, 2.5, 1.25, and 0.625mL of the culture supernatant of the Staphylococcus epidermidis strain, respectively, and the remaining volume was supplemented to 10mL with BHI. In the aerobic supernatant group, an equal amount of Staphylococcus aureus was added to each tube, and aerobic culture was carried out at 37℃, and OD was measured at 0h, 4h, 6h, and 9h, respectively. 600 Draw a bacterial growth curve to detect the growth rate of Staphylococcus aureus; in the anaerobic supernatant group, add an equal amount of Prevotella intermedia to each tube, culture anaerobically at 37°C, and measure OD at 0h, 24h, 48h and 72h 600 Draw a bacterial growth curve to detect the growth rate of Prevotella intermedia. In the anaerobic supernatant group, add an equal amount of Fusobacterium nucleatum to each tube and culture anaerobically at 37°C. OD was measured at 0h, 12h, 15h, and 18h. 600 The bacterial growth curve was drawn to detect the growth rate of Fusobacterium nucleatum; the antibacterial effect of the culture supernatant of Staphylococcus epidermidis strains with different concentrations was compared. Figure 7 It can be seen from the figure that the culture supernatant of Staphylococcus epidermidis LY1 can significantly inhibit the growth of opportunistic pathogens.
[0058] Example 5: Effect of Staphylococcus epidermidis LY1 on the innate immunity level of epithelial cells
[0059] One day before the experiment, nasopharyngeal carcinoma epithelial cells HNE1 were cultured at 4×10 5 The cells were inoculated into a 6-well plate at a density of 10 cells and cultured in a 37°C incubator for 24 h. The Staphylococcus epidermidis LY1 monoclonal was inoculated into 10 mL BHI medium and cultured aerobically at 37°C and 220 rpm for 12 h. The cells were centrifuged at 3000 rpm for 5 min, the supernatant was removed, and the cells were resuspended in 1640 culture medium. The OD was measured. 600Count, add to HNE1 cell line with MOI=10 multiplicity of infection, that is, bacteria: cell number ratio=10:1, and the control group is a group without bacteria, and co-culture in a 37°C incubator for 4 hours. Then remove the co-culture supernatant, wash 3 times with PBS, and replace with medium containing vancomycin with a final concentration of 250μg / mL for 24 hours. After the culture is completed, collect the cell culture supernatant, centrifuge at 4°C 1500rpm for 10 minutes, take the supernatant and filter it through a 0.22μm filter membrane, and use the 27-factor Luminex liquid suspension chip to detect various cytokines in the cell culture supernatant. The results are shown in Figure 8 .
[0060] The results showed that the levels of IL-5, IL-17 and IP-10 in the culture supernatant of HNE1 cells treated with Staphylococcus epidermidis LY1 were 2.2 times, 3.5 times and 3.0 times that of the untreated group, respectively, and the expression levels were significantly upregulated, indicating that Staphylococcus epidermidis LY1 can significantly increase the expression of innate immune cytokines in epithelial cells.
[0061] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.
Claims
1. A strain of Staphylococcus epidermidis, Features It was named Staphylococcus epidermidis LY1 and preserved in Guangdong Microbial Culture Collection Center, abbreviated as GDMCC, address: Institute of Microbiology, Guangdong Academy of Sciences, 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, with the preservation number GDMCC No: 64350 and the preservation date of January 31, 2024.
2. A biological agent, Features Prepared based on the Staphylococcus epidermidis described in claim 1.
3. Use of the Staphylococcus epidermidis according to claim 1 or the biological preparation according to claim 2 in the preparation of a medicine or probiotic preparation against at least one of Epstein-Barr virus, Staphylococcus aureus, Fusobacterium nucleatum and Prevotella intermedia.
4. Use of the Staphylococcus epidermidis according to claim 1 in the preparation of a medicine or probiotic preparation for inhibiting infection by at least one of Epstein-Barr virus, Staphylococcus aureus, Fusobacterium nucleatum and Prevotella intermedia or regulating mucosal immune response.
5. Use of the Staphylococcus epidermidis according to claim 1 in the preparation of medicines or probiotic preparations against Epstein-Barr virus infection.
6. Use of the biological preparation according to claim 2 in the preparation of a drug or probiotic preparation for inhibiting infection by at least one of Epstein-Barr virus, Staphylococcus aureus, Fusobacterium nucleatum and Prevotella intermedia or regulating mucosal immune response.
7. Use of the biological preparation according to claim 2 in the preparation of drugs or probiotic preparations against Epstein-Barr virus infection.
8. The use according to any one of claims 3 to 7, Features The medicine or probiotic preparation contains the Staphylococcus epidermidis strain, or a culture product thereof, or a fermentation culture fluid thereof.
9. The use according to any one of claims 3 to 7, Features The medicine or probiotic preparation is in the form of an oral liquid, a spray or a powder.
